
Johnson & Johnson acquires Ollin Biosciences for $2.2B upfront to challenge Roche's Vabysmo in eye disease | Gif: Bounce_TV on Giphy
All the top Biotech & Pharma news in one daily newsletter.
Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣
✅ The Good News ✅
THE GOOD
Approvals & Labels
FDA clears AstraZeneca's Imfinzi (durvalumab) plus Pfizer and Astellas' Padcev (enfortumab vedotin) for muscle-invasive bladder cancer following Ph3 success
Antibody, cancer, monoclonal antibody, bladder cancer, PD-L1 inhibitor, combination therapy - Read more
Tandem Diabetes Care wins FDA clearance for Tandem Mobi tubeless automated insulin delivery system for diabetes
Medical device, metabolic, automated insulin delivery, diabetes, tubeless insulin pump - Read more
AstraZeneca's Klygefa (gefurulimab) wins U.S. and EU approval for anti-AChR-positive generalized myasthenia gravis
Antibody, autoimmune, monoclonal antibody, myasthenia gravis, complement C5 inhibitor - Read more
FDA approves Roche's Gazyva (obinutuzumab) for primary membranous nephropathy in Ph3 MAJESTY trial win
Antibody, autoimmune, monoclonal antibody, primary membranous nephropathy, anti-CD20, B-cell depletion - Read more
Akeso's gumokimab (IL-17A) wins NMPA approval for active ankylosing spondylitis following Ph3 success
Antibody, autoimmune, monoclonal antibody, ankylosing spondylitis, IL-17A, anti-inflammatory - Read more
THE GOOD
Business Development & Partnerships
Charles River Laboratories acquires two Frontage bioanalysis labs in Pennsylvania for $470M upfront, $75M milestones
Acquisition, bioanalysis, small molecule, drug discovery, milestone payments - Read more
Biogen, TrimTech Therapeutics partner on neurodegeneration protein degraders, $411M deal, $32M upfront and research milestones
Licensing deal, neurological, small molecule, protein degradation, milestone payments - Read more
Astellas, Immuneering collaborate on atebimetinib studies for CLDN18.2-positive pancreatic cancer
Clinical collaboration, oncology, small molecule, drug discovery - Read more
Unlearn, Structure Therapeutics collaborate to apply AI-generated digital twins in obesity research
Research collaboration, obesity, AI/ML, small molecule, drug discovery - Read more
Novartis licenses OBI Pharma's ADC platform technologies for next-generation oncology therapies, $30M upfront, $2B+ deal
Licensing deal, oncology, antibody-drug conjugate, milestone payments, royalties - Read more
Insilico Medicine, Luoxin Pharmaceuticals partner on AI-driven R&D for digestive and metabolic chronic diseases
Research collaboration, AI/ML, drug discovery, metabolic disease, R&D - Read more
PRESENTED BY SCIENCE 2 SALES
Outbound and commercial intelligence built exclusively for selling into biopharma.

Science 2 Sales is the outbound engine for companies selling into biotech & pharma. We handle the market intelligence, prospect scoring, email sequences, LinkedIn outreach, and cold calling - so your sales team inherits a full calendar of qualified meetings.
Built by biopharma BD & sales reps, exclusively for biopharma commercial teams. It’s the platform and service we wish we had years ago.
✅ More Good News ✅
THE GOOD
Clinical Trials
Regeneron Pharmaceuticals' (baloncibart) Ph2 trial shows heart rate reduction in postural orthostatic tachycardia syndrome, advancing to Ph3
Antibody, cardiovascular, monoclonal antibody, postural orthostatic tachycardia syndrome, NPR1 blockade - Read more
Wave Life Sciences reports Ph1 data supporting body composition–based Ph2a design for (WVE-007) in obesity
Small molecule, metabolic, GalNAc-siRNA, obesity, activin E, body composition - Read more
Novo's (CagriSema) demonstrates over 20% weight loss at lower doses in Ph3 obesity trial
Protein therapy, metabolic, GLP-1 receptor agonist, obesity, amylin analog, combination therapy - Read more
Rezolute's (ersodetug) hits Ph3 primary endpoint in tumor hyperinsulinism, boosting insulin receptor antibody program
Antibody, metabolic, monoclonal antibody, hyperinsulinism, insulin receptor - Read more
Pasithea Therapeutics reports positive Ph1/1b data for (PAS-004) MEK inhibitor in neurofibromatosis type 1-associated neurofibromas
Small molecule, neurological, MEK inhibitor, neurofibromatosis type 1, oral therapy - Read more
Intellia Therapeutics shares Ph3 four-year durability data for (lonvoguran ziclumeran) targeting hereditary angioedema via KLKB1 gene editing
Gene therapy, autoimmune, CRISPR, hereditary angioedema, KLKB1, kallikrein inhibition - Read more
THE GOOD
Company Launches
Seawolf Therapeutics launches with $100M to advance DNA-based therapies and signs Sanofi deal worth up to $1.2B in milestones
Gene therapy, DNA therapeutics, lipid nanoparticles, rare disease, metabolic disease, platform technology - Read more
THE GOOD
Fundraises
Windward Bio raises $175M IPO, advancing antibody treatment for asthma and COPD
Antibody, respiratory disease, asthma, COPD, clinical-stage - Read more
Sofinnova Partners raises €725M ($815M) crossover fund to invest in late-stage drugmakers and device developers
Venture capital, life sciences, crossover financing, medical devices - Read more
Evotec receives $2.9M Gates Foundation grant to advance stem cell-based fetal drug safety testing
Drug safety, stem cell technology, platform technology, CRO, drug discovery - Read more
THE GOOD
Investments
Flagship Pioneering commits £100M ($132M) to launch AI-focused biotech incubation lab in London
AI-native platform, life sciences, strategic, major transaction - Read more
THE GOOD
Mergers & Acquisitions
Eli Lilly to acquire Calytrix Bio for up to $1.5B, targeting biparatopic antibody for blood cancers
Biparatopic antibody, oncology, major transaction, strategic - Read more
Johnson & Johnson acquires Ollin Biosciences for $2.2B upfront to challenge Roche's Vabysmo in eye disease
Bispecific antibody, ophthalmology, major transaction, strategic - Read more
THE GOOD
Politics & Policy
HHS invests up to $25M in ibogaine, psychotropic drugs for veterans' PTSD treatment
Psychedelic compound, mental health, financial, strategic - Read more
THE GOOD
Product Launches
Sandoz launches Enzeevu biosimilar in US, signs multi-year private-label agreement for retinal diseases
Private label agreement, biosimilar, ophthalmology, manufacturing, commercialization - Read more
THE GOOD
Regulatory
American Cancer Society updates prostate cancer screening guidelines for first time in 16 years
Diagnostics, oncology, clinical guidelines - Read more
THE GOOD
Strategic Plans
Teva targets $6B–$7B in innovative drug sales by 2030, doubling current revenue
Small molecule, neurological, strategic, revenue impact - Read more
PRESENTED BY YOU?
Get the attention of 3000+ Biotech & Pharma Professionals 🤩

Gif: mostexpensivest on Giphy
Do you offer a biotech/pharma-focused product or service?
Or looking to get investor/analyst interest on your budding start-up?
Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.
Just reply to this email* or message me on LinkedIn to learn more.
*If you’re reading this on the web version, email [email protected]
❌ The Bad News ❌
THE BAD
Approvals & Labels
FDA rejects Summit Therapeutics' (ivonescimab) for EGFR-mutated non-small cell lung cancer following Ph3 overall survival miss
Antibody, cancer, bispecific antibody, non-small cell lung cancer, PD-1, VEGF - Read more
THE BAD
Clinical Trials
Aclaris Therapeutics' (bosakitug) anti-TSLP antibody fails Ph2 primary endpoint in moderate-to-severe atopic dermatitis
Antibody, autoimmune, monoclonal antibody, atopic dermatitis, TSLP target - Read more
THE BAD
Layoffs
Cellectis to cut up to 70% of workforce amid strategic shift to in vivo gene editing therapies
Gene therapy, cardiovascular, strategic, cost reduction - Read more
AstraZeneca cuts 600 U.S. respiratory and immunology sales jobs amid $1.5B cost-savings restructuring plan
Small molecule, respiratory, cost reduction, operational - Read more
THE BAD
Market Reports
IQVIA finds 90% of new medicines launched 2016–2020 unprofitable amid soaring R&D costs
Pharmaceutical industry, multiple disease areas, financial, operational, R&D costs - Read more
THE BAD
Regulatory
Candel Therapeutics shares drop 38% after FDA filing delay for prostate cancer viral immunotherapy to mid-2027
Viral immunotherapy, oncology, regulatory, operational - Read more
You’re all caught up on the latest Pharma & Biotech News!
TLDR Biotech wants to hear from you! 📣
Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝
If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️
And lastly - connect with me on LinkedIn!

Thanks for reading! -Anis
Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here


